Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Integrated BioPharma ( (INBP) ) is now available.
On December 1, 2025, Integrated BioPharma, Inc. held its 2025 Annual Meeting of Stockholders, where 22,651,488 shares were represented, forming a quorum. The stockholders voted on four proposals, including the election of Eric Friedman as Class III director, a non-binding advisory vote on executive compensation frequency, approval of executive compensation, and ratification of CBIZ CPAs P.C. as independent auditors for the fiscal year ending June 30, 2026.
The most recent analyst rating on (INBP) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Integrated BioPharma stock, see the INBP Stock Forecast page.
Spark’s Take on INBP Stock
According to Spark, TipRanks’ AI Analyst, INBP is a Neutral.
Integrated BioPharma’s overall stock score is driven by its solid financial performance, particularly in cash flow generation and reduced leverage. The technical analysis suggests a stable trend, though with some bearish signals. The valuation is reasonable, but the lack of a dividend yield may deter income investors.
To see Spark’s full report on INBP stock, click here.
More about Integrated BioPharma
Average Trading Volume: 16,255
Technical Sentiment Signal: Hold
Current Market Cap: $9.78M
See more data about INBP stock on TipRanks’ Stock Analysis page.